- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03815630
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors (DC-CIK)
January 28, 2019 updated by: Allife Medical Science and Technology Co., Ltd.
Clinical Study on the Safety and Efficacy of Pd-1 Combined With Dc-cik in the Treatment of Solid Tumors
This is a single center、single arm、open-label, to investigate the safety and efficacy of PD-1 and DC-CIK with anti-solid tumor
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Early Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Previously receiving ≥ first-line regimen chemotherapy;
- Age over 3 years old and less than 14 years old;
- The expected survival period is more than 3 months;
- ECOG≤2;
- Vital organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction ≥ 50%, no obvious abnormality in ECG; blood oxygen saturation ≥ 90%; creatinine clearance calculated by Cockcroft-Gault formula ≥ 40ml/min; ALT and AST ≤ 3 times the normal range, total bilirubin ≤ 2.0 mg / dl;
- Blood routine: Hgb≥80g/L, ANC≥1×109/L, PLT≥50×109/L;
- There are measurable target lesions.
Exclusion Criteria:
Liver and kidney function:
- Total bilirubin > 2 x ULN (Gilbert syndrome > 3 x ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 × ULN
- Serum creatinine clearance >60mL/min
Serological examination:
- Absolute neutrophil count (ANC) <0.75x109/L
- Platelet count (PLT) <50x109/L
- Active hepatitis B (HBV-DNA > 1000 copies / ml), hepatitis C, or uncontrolled infection;
- The number of days of chemotherapy medication and the administration of hormones below 5mg is ≤3, and the number of days of withdrawal of hormones greater than 5mg is ≤5;
- Active CNS disease (tumor cells in CSF);
- Intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation;
- creatinine > 1.5 times the upper limit of normal or ALT / AST > 3 times the upper limit of normal or bilirubin > 2 times the upper limit of normal;
- The New York Heart Association (NYHA) is classified as Level III or higher;
- Uncontrolled diabetes;
- With other uncontrolled diseases, the investigator believes that it is not suitable for joining;
- Any situation that the investigator believes may increase the risk of the subject or interfere with the test results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PD-1 and dc-cik treatment group
|
Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
occurrence of treatment related adverse events
Time Frame: 1 year
|
occurrence of treatment related adverse events that are possible, likely.
Or definitely related to study treatment.
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 1, 2019
Primary Completion (Anticipated)
February 1, 2020
Study Completion (Anticipated)
February 1, 2021
Study Registration Dates
First Submitted
January 21, 2019
First Submitted That Met QC Criteria
January 23, 2019
First Posted (Actual)
January 24, 2019
Study Record Updates
Last Update Posted (Actual)
January 30, 2019
Last Update Submitted That Met QC Criteria
January 28, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PD-1/DC CIK-YNYY-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on pd-1 and dc-cik cells
-
Dalian UniversityUnknownNon-small Cell Lung Cancer
-
Fuda Cancer Hospital, GuangzhouJinan University GuangzhouCompleted
-
Capital Medical UniversityDuke UniversityCompleted
-
Capital Medical UniversityDuke University; Geneplus-Beijing Co. Ltd.CompletedNeoplasms | Lung CancerChina
-
Fuda Cancer Hospital, GuangzhouJinan University GuangzhouCompleted
-
Xiaoyi HuangUnknownRenal Cell Carcinoma | Nasopharyngeal Carcinoma | Colorectal Cancer | Lung CancerChina
-
Guangxi Medical UniversityUnknown
-
Second Military Medical UniversityUnknownAdvanced Hepatocellular CarcinomaChina
-
Allife Medical Science and Technology Co., Ltd.Beijing Hospital; Henan Provincial People's Hospital; The First People's Hospital...Unknown